New Releases from NCBI BookshelfNivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer.​Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer.

Post Content

​ 

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top